At Chimerocyte scientists develop molecular technologies to detect and quantify allogeneic cells and/or DNA at levels of sensitivity and specificity that are not reached by currently available techniques. The objective is creating a highly sensitive quantitative chimerism test for use in clinical diagnostics, as well as for scientific research. Identification of Minimal Residual Disease (MRD) in leukemia is highly predictive of relapse, especially important in patients with poor prognosis and undergoing allogeneic hematopoietic transplantation as a curative therapy. The technology can simultaneously monitor chimerism dynamics post-transplant, and because it is highly sensitive can identify patients with higher risk of relapse based on chimerism analysis as a surrogate marker for MRD. Moreover, because the assays have specificities towards HLA genes, they can detect in some cases loss of HLA heterozygosity, a mechanism recognized to be used by cancer cells to evade the immune system and contribute to relapse.